Quantcast

Merck: A Slow And Steady Big Pharma Dividend Grower, But Better Alternatives Exist

Posted On November 13, 2017 8:32 am
By:

Merck has long been known as a boring, and safe dividend investment. While that may be true, the company’s numerous challenges and slow growth rate mean there are better drug makers to buy today.

Continue Reading Here

About author

Dividend Sensei
Dividend Sensei

I’m an Army veteran and former energy dividend writer for The Motley Fool. I currently write for both Seeking Alpha, Simply Safe Dividends, Investorplace.com, and TheStreet.com.

My goal is to help all people learn how to harness the awesome power of dividend growth investing to achieve their financial dreams, and enrich their lives. With 20 years of investing experience, I’ve learned what works and more importantly, what doesn’t, when it comes to building long-term wealth and income streams. I’m currently on an epic quest to build a broadly diversified, high-quality, high-yield dividend growth portfolio that:

1. Pays a 4% to 5% yield
2. Offers 9% to 10% annual dividend growth
3. Pays dividends AT LEAST on a weekly, but preferably, daily basis

Related Articles